BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sjögren's Disease readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Sjögren's Disease\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07836660-5453@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Telitacicept: Phase 2 readout est. (NCT07836660)
DESCRIPTION:Telitacicept\, phase 2\, Sjögren's Disease.\nStudy: A Study of
  IBI355 in Participants With Moderate-to-Severe Sjögren's Disease\nEstima
 ted primary completion: 1 November 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/telitacicept#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07836660
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979531-10825@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Imeroprubart: Phase 2 readout est. (NCT06979531)
DESCRIPTION:Imeroprubart\, phase 2\, Sjögren's Disease.\nStudy: Efficacy a
 nd Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Diseas
 e With Moderate to Severe Systemic Disease Activity\nEstimated primary com
 pletion: July 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/i
 meroprubart#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06979531
URL:https://assetmemo.bio/drug/imeroprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07404865-5453@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Telitacicept: Phase 3 readout est. (NCT07404865)
DESCRIPTION:Telitacicept\, phase 3\, Sjögren's Disease.\nStudy: Phase 3 St
 udy of Telitacicept in Active Primary Sjögren's Disease\nEstimated primar
 y completion: December 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/telitacicept#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07404865
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07737743-10879@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20290219
DTEND;VALUE=DATE:20290220
SUMMARY:MRT-6160: Phase 2 readout est. (NCT07737743)
DESCRIPTION:MRT-6160\, phase 2\, Sjögren's Disease.\nStudy: A Phase 2a/b S
 tudy to Assess the Efficacy\, Safety and Tolerability of DDY391 in Partici
 pants With Sjögren's Disease\nEstimated primary completion: 19 February 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/mrt-6160#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07737743
URL:https://assetmemo.bio/drug/mrt-6160#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621809-10731@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20290815
DTEND;VALUE=DATE:20290816
SUMMARY:VAY736: Phase 3 readout est. (NCT07621809)
DESCRIPTION:VAY736\, phase 3\, Sjögren's Disease.\nStudy: Two Arm\, Double
 -blind\, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus
  Placebo\, in Participants With Sjögren's Disease With High Symptom Burde
 n\nEstimated primary completion: 15 August 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/vay736#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07621809
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07791199-100@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Sotyktu (deucravacitinib): Phase 3 readout est. (NCT07791199)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 3\, Psoriatic Arthritis.\nStu
 dy: Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric Ps
 O/PsA Study Completers\nEstimated primary completion: 31 October 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/deucravacitinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07791199
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
